FLUDEOXYGLUCOSE (F-18) SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

FLUDEOXYGLUCOSE 18F

Saatavilla:

LAWSON HEALTH RESEARCH INSTITUTE

ATC-koodi:

V09IX04

INN (Kansainvälinen yleisnimi):

FLUDEOXYGLUCOSE (18F)

Annos:

232GBQ

Lääkemuoto:

SOLUTION

Koostumus:

FLUDEOXYGLUCOSE 18F 232GBQ

Antoreitti:

INTRAVENOUS

Kpl paketissa:

20ML

Prescription tyyppi:

Schedule C

Terapeuttinen alue:

ROENTGENOGRAPHY

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0152591014; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2018-10-02

Valmisteyhteenveto

Fludeoxyglucose (
18
F)
1
PRODUCT MONOGRAPH
TRADE NAME
Fludeoxyglucose (
18
F) Injection
0.5 to 232 GBq/vial
Diagnostic Radiopharmaceutical
Lawson Health Research Institute
268 Grosvenor Street
London ON N6A 4V2
Date of Approval:
March 9, 2017
Control #:
197018
Fludeoxyglucose (
18
F)
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
DESCRIPTION
...............................................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
4
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................................................
5
ADVERSE REACTIONS
...............................................................................................................
6
DRUG INTERACTIONS
...............................................................................................................
6
DOSAGE AND ADMINISTRATION
...........................................................................................
7
RADIATION DOSIMETRY
..........................................................................................................
9
OVERDOSAGE............................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
11
STORAGE AND STABILITY
.....................................................................................................
12
SPECIAL HANDLING INSTRUCTIONS
..................................................................................
12
DOSAGE FORM